Management of Hyperkalemic Periodic Paralysis
For hyperkalemic periodic paralysis (HyperPP), initiate dichlorphenamide as first-line prophylaxis to reduce attack frequency, with acetazolamide as an alternative if dichlorphenamide is unavailable or not tolerated. 1, 2
Acute Attack Management
During an acute paralytic episode, the priority is rapid potassium lowering and symptom relief:
- Avoid potassium-rich foods and triggers during the attack (high-potassium meals, rest after exercise, cold exposure) 3
- Administer glucose with insulin if severe weakness is present, as this shifts potassium intracellularly within 30-60 minutes 4
- Consider inhaled beta-agonists (salbutamol 20 mg nebulized) for additional intracellular potassium shift 4
- Monitor for cardiac complications with ECG, as hyperkalemia can cause arrhythmias even in HyperPP patients 5, 4
Critical perioperative consideration: Absolutely avoid depolarizing neuromuscular blockers (succinylcholine) in any surgical setting, as these can trigger severe paralysis and hyperkalemia 3
Long-Term Prophylactic Management
First-Line: Dichlorphenamide
Dichlorphenamide significantly reduces attack frequency and improves quality of life in HyperPP patients. 1, 2
- In the pivotal randomized trial, median attack rate decreased from 4.8 attacks/week on placebo to 0.9 attacks/week on dichlorphenamide in HyperPP patients 1
- 15 of 16 patients preferred dichlorphenamide over placebo or baseline medication 1, 2
- Common side effects include paresthesias (47%) and confusion (19%), which should be discussed with patients 1
Second-Line: Acetazolamide
Acetazolamide is highly effective for long-term prophylaxis and can reverse permanent weakness in some HyperPP patients. 6, 7
- Acetazolamide lowers plasma potassium from approximately 4.55 to 4.00 mEq/L in HyperPP patients through its kaliopenic effect 7
- Remarkable benefit on permanent weakness: One case demonstrated complete recovery from late-onset permanent weakness with increased muscle bulk on MRI, sustained over 6 years 6
- Continue acetazolamide indefinitely if effective, as discontinuation may lead to recurrence of weakness 6
- Particularly effective in patients with the common T704M SCN4A mutation 6
Emerging Therapy: GLP-1 Agonists
Semaglutide shows promise as a novel treatment for both episodic attacks and chronic myopathy in HyperPP. 8
- A 48-year-old patient with refractory HyperPP (unresponsive to acetazolamide and dichlorphenamide) regained ability to rise from a chair independently after semaglutide initiation 8
- Mechanism: Direct action on skeletal muscle both insulin-dependent and insulin-independent, potentially treating both paralysis and muscle atrophy 8
- Consider as alternative therapy when carbonic anhydrase inhibitors fail or are not tolerated 8
Ongoing Monitoring and Prevention
Continue prophylactic therapy indefinitely, as HyperPP is a chronic genetic condition requiring lifelong management. 5, 6
- Monitor serum potassium 2-4 times yearly once stable on therapy 5
- Educate patients on trigger avoidance: high-potassium foods, prolonged rest after exercise, cold exposure, fasting 3, 9
- Continue potassium-wasting diuretics through any surgical procedures 3
- Assess for development of permanent myopathy at regular intervals, as progressive proximal weakness can develop despite prophylaxis 6, 9
Critical Pitfalls to Avoid
- Never use depolarizing neuromuscular blockers (succinylcholine) in surgical settings—this is an absolute contraindication 3
- Do not discontinue prophylactic therapy during asymptomatic periods, as attacks will recur 5, 6
- Avoid potassium-sparing diuretics and ACE inhibitors/ARBs that could exacerbate hyperkalemia 4
- Ensure thermoregulation during surgery, as hypothermia can trigger attacks 3